London, UK – Experts are issuing warnings following reports of a surge in pregnancies linked to the use of weight-loss medications such as Wegovy and Ozempic, commonly referred to as “skinny jabs.” Women are being advised to exercise caution and use effective contraception while using these drugs to avoid unintended pregnancies.
These medications, containing semaglutide, have gained popularity for their ability to help individuals shed over 10% of their body weight by mimicking a hormone in the body called GLP-1, which regulates insulin production, slows down digestion, and suppresses appetite. However, the rise in reported pregnancies among women on these medications, known as GLP-1 receptor agonists, has raised concerns among experts.
Although formal studies establishing a direct link are lacking, experts suggest there may be a plausible association between weight loss and increased fertility in women with obesity. Research is currently underway to explore whether semaglutide could potentially enhance ovulation in women with obesity and polycystic ovary syndrome (PCOS), a condition that can lead to irregular periods, weight gain, and infertility.
While there is limited clinical trial data on the use of semaglutide in pregnant women, animal studies have indicated potential risks of fetal abnormalities. Novo Nordisk, the pharmaceutical company behind Ozempic and Wegovy, advises against using semaglutide during pregnancy due to uncertainties about its impact on unborn children.
Individual reports of women becoming pregnant while on hormonal contraception and using GLP-1 receptor agonists have sparked speculation about a possible interference with contraceptive methods. Experts, like Prof Sir Stephen O’Rahilly, emphasize the need for further research to address concerns about the efficacy of oral contraceptives when used alongside these weight-loss drugs.
In light of these potential risks, women using drugs like Ozempic are encouraged to consider additional contraceptive measures, such as condoms or intrauterine devices (IUDs), in combination with their current method. By being proactive and taking extra precautions, women can better safeguard themselves against unplanned pregnancies while undergoing weight-loss treatment with GLP-1 receptor agonists.